Stoke therapeutics, inc. (STOK)
CashFlow / Yearly
Dec'19Dec'18
Cash flows from operating activities:
Net loss

-32,325

-12,521

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

450

214

Stock-based compensation

1,922

240

Loss on disposal of property and equipment

-3

-10

Changes in assets and liabilities:
Prepaid expenses and other current assets

2,024

632

Accounts payable and accrued liabilities

891

1,735

Deferred rent

28

-10

Net cash used in operating activities

-31,055

-10,964

Cash flows from investing activities:
Purchases of property and equipment

1,635

935

Proceeds from sale of property and equipment

1

10

Net cash used in investing activities

-1,634

-925

Cash flows from financing activities:
Proceeds from issuance of convertible Preferred Stock

-

116,000

Preferred Stock Issuance Cost

-

378

Proceeds from issuance of common stock upon initial public offering

151,912

-

Payments of initial public offering costs

2,463

-

Proceeds from issuance of common stock upon exercise of stock options

315

19

Other

-2

-2

Net cash provided by (used in) financing activities

149,762

115,639

Net decrease in cash, cash equivalents and restricted cash

117,073

103,750

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Property and equipment included in accrued expense and accounts payable

140

19

Issuance of convertible Preferred Stock in exchange for simple agreement for future equity

-

3,000